rituximab,acalabrutinib
astrazeneca
['rituximab', 'lymsm', 'acalabrutinib', 'cml', 'ritux']
congress |#17icml , presents phase ii trial results showing high efficacy and safety of acalabrutinib plus rituximab as first-line therapy in elderly pts with mcl. best responses was an orr and cr of 92%, with mrd negative remissions achieved. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm